TTC17

Across TCGA pan-cancer cohorts, TTC17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC17 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TTC17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TTC17 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where TTC17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.408	0.903	<.001	56	view →
LUAD	DFS	Tertile	II,III,IV	0.315	0.647	.013	12	view →
PDAC	OS	Median	IV	0.951	0.381	.006	9	view →
HNSC	OS	Quartile	All	0.857	0.947	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC17–CCRCC (OS)

Open the CCRCC breakdown →